Dish of the day
No Joiners Today
Off the menu
No Leavers Today
What’s cooking in the IPO kitchen?
The pantry is empty, again!
Banquet Buffet
Sigma Capital 86p £77m (AIM:SGM)
Appointment of Ian Sutcliffe as Non-executive Chairman with immediate effect. Ian brings a wealth of board level experience in both house building and other companies. Most recently he was Group Chief Executive of Countryside Properties plc, until his retirement earlier this year, and Senior Independent Director at Ashtead Group plc. He was also previously UK Chief Executive of Taylor Wimpey plc and Chief Operating Officer of SEGRO plc. Current Chairman David Sigsworth will remain on the Sigma board as Senior Independent Non-executive Director.
Get Busy 63.5p £31.05m (AIM:GETB)
First 4 months trading in 2020. On a constant currency basis, recurring revenue and total revenue grew by 20% and 15% respectively in the Period. Recurring revenue represented 90% of the Group's total revenue in the Period.
Mixed immediate impact of Covid-19 on customers. “There is an increased risk of customers churning or reducing licensed user numbers as they cut staffing levels, albeit we have yet to see significant examples of this. We have, however, seen some clear stretching of payment terms by customers in the UK, and some customers have asked to switch from our annual subscription plans to monthly-paid plans as their own cashflow has been challenged since the global lockdowns. Importantly, no single customer accounts for more than 1% of our recurring revenue, which helps mitigate risk. “ “The surge in remote working requires a new software toolset for many organisations and each of our products is a component of that toolset..”
FARON Pharma 370p £173m (AIM:FARN)
A global contract development and manufacturing organisation AGC Biologics has been selected to be the commercial scale manufacturer of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAMs) in selected metastatic or inoperable solid tumours.
The recent clinical progress with Clevegen and recommendations from the data monitoring committee of the ongoing phase I/ II MATINS study to expand Clevegen's development across nine different cancer types indicate a requirement for increased Clevegen drug substance.
Tekmar Group 120p £61.5m (LON:TGP)
Trading update ahead of the Group's results for the year ended 31 March 2020, which are expected to be in line Revenue in the Period is expected to be in line with expectations, showing above 40% growth on the prior financial year. This significant increase in sales has been achieved, despite the lockdown and social distancing measures associated with COVID-19 impacting the Group's activity in the heavily Q4 weighted period.
The Group ended the Period with a record year end Order Book1 of no less than £10 million, up 39% on the prior year end (FY19: £7.2m).with market expectations. The Group has continued to operate across all of its sites throughout the lockdown.
Kingswood Holdings 17p £37m (LON:KWG)
Announcement of the formal closing of the Chalice acquisition and that it has signed conditional heads of terms to assume majority ownership in Manhattan Harbor Capital. These businesses will be rebranded Kingswood US and put the Company in a strong position to drive its US growth strategy. On completion, Kingswood will have circa 180 authorised representatives managing AUM of circa $2 billion (£1.6 billion) in the United States.
Motif Bio 1.25p £6.1m (AIM:MTFB)
The AIM Rule 15 cash shell has raised £650k at 0.4p. The Company's Directors are currently in discussions with several companies in the healthcare sector that have expressed an interest in proceeding with a reverse takeover, although at this stage no assurances can be provided that the effort will be successful to source and/or complete a reverse takeover transaction.
Following its reclassification as an AIM Rule 15 cash shell in January 2020, the Company is required to make an acquisition which constitutes a reverse takeover under the AIM Rules by 28 July 2020.
Gaming Realms 9.75p £27.7m (AIM:GMR)
The developer and licensor of mobile focused, real money games, has extended its licensing and revenue share agreement with 888 Holdings plc.
Under the terms of the partnership, Gaming Realms' existing agreement with 888, announced on 15 January 2018, has been extended to include 888casino.com. 888, which hosts Gaming Realms' Slingo games on its Dragonfish B2B platform, has now also launched the entire Slingo Originals portfolio, distributed via Gaming Realms' aggregation partner SG Digital, on its leading B2C site 888casino.com.
EKF Diagnostics 41.5p £188.5m (AIM:EKF)
The point-of-care business, announces that it has signed a three-year distribution agreement with Tosoh Europe N.V., part of Tosoh Corporation, the global chemical and specialty materials company, for the distribution of the Company's Quo-Test HbA1c Analyzer in the Middle East and Africa.
EKF's Quo-Test is a fully automated desktop HbA1c (glycated hemoglobin) analyzer that provides easy and reliable HbA1c measurement for monitoring and managing diabetes in a Point-of-Care setting, such as diabetes clinics and doctors' surgeries. The sample results are available within four minutes from a 4 microliter sample taken from a finger prick or venous whole blood. Step by step instructions displayed on the Quo-Test analyzer's clear, multi-lingual display, reduce staff training time to a minimum, eliminating the opportunity for user-related errors. The Tosoh Bioscience division is one of the largest global manufacturers of High Performance Liquid Chromatography (HPLC) equipment for glycated hemoglobin analysis, offering scalable solutions predominantly in core laboratories.
Entertainment AI 27p £13.5m (LON:EAI)
The technology and media platform company focused on transforming video content and e-commerce through micro-moments, announces its trading update for year-to-date through the end of the first quarter.
Adjusted profits before tax were in line with expectations. Whilst the Group's Multi-Channel Network showed strong growth in audience views and watch minutes, because of the impact of Covid-19 and the market-wide reduction in digital video advertising spend, the Company does not expect this growth to translate into a similar increase in revenue. However, the Company has maintained a strong balance sheet with cash of $7.9m as at 30th April and remains on track to launch its new AI-driven products on schedule in May and June.
Sensyne Health 49.5p £63.6m (AIM:SENS)
Sensyne Health announces launch of new BPm-Health ™ remote monitoring system for the management of blood pressure in pregnancy in response to COVID-19 pandemic
Highlights :
· BPm-Health ™ will enable pregnant women to self-monitor their blood pressure during pregnancy
· Will help healthcare professionals provide remote care for mums-to-be in line with UK government guidelines on social distancing and provision of care away from hospitals & clinics
· Company will work collaboratively with the NHS to broaden use of the product across the UK
*denotes a corporate client of Hybridan LLP
Head Chef
Derren Nathan
0203 764 2344
derren.nathan@hybridan.com